important announcement:

top-line results for the lipididiet (LDD) study have now been released.

please consult the lipididiet website for more information.


To investigate the effects of Souvenaid in elderly patients at high risk of developing Alzheimer’s disease.

Primary outcome measures

The primary outcome measure is cognitive performance assessed by a modified version of the Neuropsychological Test Battery (NTB)

Study Design

Patients with prodromal AD defined by Dubois criteria[2]

Primary Outcome:
  • Z-score of the NTB (9 item)
Secondary Outcomes:
  • Progression to AD
  • Cognitive performance (ADAS-Cog, MMSE)
  • Functional Ability (ADCS-ADL)
  • Depression (MADRS)
  • MRI atrophy rate
  • Nutritional measures (blood plasma and CSF biomarkers)

The EU-funded LipiDiDiet™ study is a 24-month, randomised, controlled, double-blind, parallel-group, study aiming to recruit 300 prodromal Alzheimer’s disease subjects. Patients will be randomised to receive Souvenaid or an isocaloric control drink. Enrolment for the study is now complete, with first results expected at the end of 2015.

Related Links

Visit Website


1.Freund-Levi Y, Visser PJ, Kivipelto M, Wieggers RL, Hartmann T, Soinnen H. The LipiDiDiet study: rationale and study design. CtAD, San Diego, November 2011; J Nutr Health Aging 2011;15 (Suppl 1)

2.Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., … & Scheltens, P. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. The Lancet Neurology, 2007;6(8), 734-746.